Literature DB >> 8612130

Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading.

R J Riese1, P R Wolf, D Brömme, L R Natkin, J A Villadangos, H L Ploegh, H A Chapman.   

Abstract

Destruction of li by proteolysis is required for MHC class II molecules to bind antigenic peptides, and for transport of the resulting complexes to the cell surface. The cysteine protease cathepsin S is highly expressed in spleen, lymphocytes, monocytes, and other class II-positive cells, and is inducible with interferon-gamma. Specific inhibition of cathepsin S in B lymphoblastoid cells prevented complete proteolysis of li, resulting in accumulation of a class II-associated 13 kDa li fragment in vivo. Consequently, the formation of SDS-stable complexes was markedly reduced. Purified cathepsin S, but not cathepsin B, H, or D, specifically digested li from alpha beta li trimers, generating alpha beta-CLIP complexes capable of binding exogenously added peptide in vitro. Thus, cathepsin S is essential in B cells for effective li proteolysis necessary to render class II molecules competent for binding peptides.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8612130     DOI: 10.1016/s1074-7613(00)80249-6

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  152 in total

1.  Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts.

Authors:  J Hansen; K Qing; A Srivastava
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains.

Authors:  K Frauwirth; N Shastri
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

3.  Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM.

Authors:  J A Villadangos; C Driessen; G P Shi; H A Chapman; H L Ploegh
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

4.  Alternative proteolytic processing of mouse mammary tumor virus superantigens.

Authors:  F Denis; N H Shoukry; M Delcourt; J Thibodeau; N Labrecque; H McGrath; J S Munzer; N G Seidah; R P Sékaly
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  Lysosomal cathepsin B plays an important role in antigen processing, while cathepsin D is involved in degradation of the invariant chain inovalbumin-immunized mice.

Authors:  T Zhang; Y Maekawa; J Hanba; T Dainichi; B F Nashed; H Hisaeda; T Sakai; T Asao; K Himeno; R A Good; N Katunuma
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

6.  Interaction of human immunodeficiency virus type 2 Vpx and invariant chain.

Authors:  H A Pancio; N Vander Heyden; K Kosuri; P Cresswell; L Ratner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

7.  Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S.

Authors:  G Guncar; G Pungercic; I Klemencic; V Turk; D Turk
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

8.  Kinetics and intracellular pathways required for major histocompatibility complex II-peptide loading and surface expression of a fluorescent hapten-protein conjugate in murine macrophage.

Authors:  D J Weaver; E W Voss
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

9.  Developmental plasticity of CNS microglia.

Authors:  L Santambrogio; S L Belyanskaya; F R Fischer; B Cipriani; C F Brosnan; P Ricciardi-Castagnoli; L J Stern; J L Strominger; R Riese
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

10.  Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity.

Authors:  Kaoru Saegusa; Naozumi Ishimaru; Kumiko Yanagi; Rieko Arakaki; Kouichi Ogawa; Ichiro Saito; Nobuhiko Katunuma; Yoshio Hayashi
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.